Soaring drug prices, delayed vaccines, unpaid support for patients with serious illnesses, and shortages of essential medicines are placing an increasing burden on Iranian families.
Iran’s medication crisis is moving beyond isolated shortages and becoming a broader threat to public health. As autumn begins and respiratory illnesses increase, Iranians are confronting delayed influenza vaccines, sharply higher medicine prices, unpaid support for patients with serious and rare diseases, and growing difficulties obtaining essential drugs.
The figures reported by Iranian officials themselves illustrate the scale of the problem. The head of the Food and Drug Administration has reported that the average price of medicines increased by approximately 103 percent since the beginning of the current Iranian year, while patients’ direct out-of-pocket payments increased by 35 percent. At the same time, the preferential foreign-currency allocation for medicines and medical equipment was reduced by approximately $900 million.
For Iranian families, these are not abstract budgetary figures. They determine whether a patient can obtain a prescription, whether a chronic illness can be treated consistently, and whether a seasonal infection can be prevented.
Influenza Vaccine Still Missing as Autumn Begins
The latest warning concerns influenza vaccination.
On September 21, the regime’s Food and Drug Administration acknowledged that no influenza vaccine had yet been officially distributed to the public for the current season. Authorities have projected that 2.8 million doses will eventually be available, while alternative supplies from China and Russia have been pursued after difficulties securing European vaccines.
The delay comes as respiratory infections are already increasing.
Health officials have warned of another influenza wave, particularly affecting children and vulnerable groups. The timing is especially significant because schools are reopening, increasing opportunities for respiratory viruses to spread.
The government has cited several external difficulties, including delays by foreign manufacturers, higher prices, financial-transfer problems, transportation difficulties, and sanctions-related restrictions. An official Health Ministry and Food and Drug Administration statement acknowledged that these factors had complicated vaccine procurement.
But the same episode also exposes the consequences of the regime’s broader policies.
Iran’s own Health Ministry has acknowledged that wartime conditions complicated procurement and transportation, while the country’s pharmaceutical system is simultaneously suffering from financial and currency pressures.
The result is that ordinary people face uncertainty over when vaccines will arrive, how much they will cost, and who will actually be able to obtain them.
A Medicine Price Shock
The vaccine shortage is only one part of the crisis.
The reported 103-percent average increase in medicine prices represents a dramatic deterioration in affordability. Patients are already paying 35 percent more directly for medicines, according to the Food and Drug Administration.
The pharmaceutical sector has also faced rising costs for imported raw materials and transportation. One report citing pharmaceutical officials noted that container shipping costs from major suppliers in China and India, previously around $2,000–$3,000, have in some cases reached approximately $30,000.
Such pressures eventually reach the patient.
When pharmaceutical production becomes more expensive, the cost is transferred through higher retail prices, increased insurance burdens, or shortages when manufacturers and distributors cannot maintain supply.
For families already struggling with inflation and declining purchasing power, even relatively small increases in essential medicines can become prohibitive.
Patients With Serious Diseases Left Waiting
The crisis is particularly severe for patients who cannot simply postpone treatment.
The regime’s own parliamentary discussions have highlighted problems surrounding the fund established to support patients with special and incurable diseases.
For 1405, the equivalent of 16 trillion tomans was reportedly allocated for the fund. Yet a dispute over whether this money constitutes a separate allocation or is included within the broader Health Insurance budget has left patients without the expected support. Parliament Speaker Mohammad Bagher Ghalibaf acknowledged that patients with serious diseases were being deprived of the funds despite the allocation appearing in the budget.
Earlier reporting also highlighted a budget shortfall affecting the fund, with tens of thousands of patients identified as requiring support.
Thus, even when money is formally included in the national budget, patients can still be left waiting when government institutions dispute responsibility for allocating it.
The consequence is a system in which patients end up paying the price for bureaucratic and fiscal failures.
Thalassemia Patients Face the Consequences
The situation facing thalassemia patients provides a particularly stark example.
Patients with thalassemia require continuing treatment to manage iron accumulation caused by repeated blood transfusions. Interrupting treatment can have serious health consequences.
According to the information reported by the Thalassemia Association in Kermanshah, the price of a 10-dose package of Desferal, an essential iron-chelation medicine, rose from approximately 50,000 tomans to 500,000 tomans.
Among 30 to 40 patients using the medicine in the region, the association reported that only two or three had managed to obtain limited quantities during the preceding two months. Even those patients could not maintain regular treatment throughout the period.
Others were reportedly forced to seek cheaper alternatives or different brands rather than consistently receiving the medication prescribed by their doctors.
For chronic patients, this is not an ordinary consumer choice. Treatment cannot simply be postponed until prices become affordable.
The Regime’s Sanctions Explanation
Iranian officials routinely attribute medicine shortages and rising costs to U.S. sanctions, banking restrictions and difficulties transferring money.
These factors can indeed complicate pharmaceutical trade. The government itself has cited international financial and transportation restrictions as contributing to the influenza vaccine delay.
But sanctions alone do not explain the entire crisis.
The sharp reduction in preferential foreign currency for medicines, the 103-percent average increase in drug prices, rising patient payments, insurance debts, budget disputes, and failures in the distribution of support funds are domestic policy and management issues.
The contradiction is particularly visible when the government claims that alternative trade routes and supplies of essential goods remain available.
If resources can be allocated to maintain imports of essential commodities, the question of how available foreign currency and public funds are prioritized becomes unavoidable.
Health Comes After the Regime’s Priorities
The medication crisis therefore reflects a larger problem in the way the regime manages Iran’s resources.
A country with a large population, substantial energy resources and a sophisticated medical community should not be forced into a situation where patients with chronic diseases struggle to obtain basic medicines or where seasonal vaccines arrive late because procurement and financial mechanisms have failed.
The problem is not simply that medicine has become more expensive.
It is that the Iranian people are increasingly being asked to absorb the cost of policies they did not choose.
Government resources are finite. When economic policy, currency allocation, military confrontation and other regime priorities consume resources, fewer resources remain available for healthcare, social protection and essential services.
The consequences appear in pharmacies and hospitals rather than in government speeches.
A patient who cannot afford a medicine does not experience the problem as an accounting dispute. A parent waiting for a vaccine does not experience it as a foreign-exchange allocation issue. A thalassemia patient unable to obtain regular treatment does not experience it as a debate between the parliament and the government.
They experience it as a threat to their health and, in some cases, to their lives.
A Crisis Created by Policy
Iran’s medication crisis is therefore becoming a measure of the regime’s priorities.
The evidence points to multiple interacting causes: international restrictions and procurement difficulties, but also reduced pharmaceutical currency support, soaring prices, insurance and budgetary failures, supply-chain problems, and the consequences of wartime conditions.
Reducing the entire crisis to sanctions obscures the domestic policy decisions that determine how Iran’s available resources are distributed.
The central question is ultimately simple: why are Iranian patients being forced to pay an ever-higher price for medicines in a country with such substantial national resources?
The answer cannot be found in pharmacies alone. It lies in the economic and political priorities of the Iran regime—and in the growing gap between the resources of the country and the basic needs of its people.